263 results on '"Arns, Wolfgang"'
Search Results
2. A paired-kidney allocation study found superior survival with HLA-DR compatible kidney transplants in the Eurotransplant Senior Program
3. Feasibility and Potential of Transcriptomic Analysis Using the NanoString nCounter Technology to Aid the Classification of Rejection in Kidney Transplant Biopsies
4. Impact of everolimus plus calcineurin inhibitor on formation of non-HLA antibodies and graft outcomes in kidney transplant recipients: 12-month results from the ATHENA substudy
5. Renal Function and Patient-Reported Outcomes in Stable Kidney Transplant Patients Following Conversion From Twice-Daily Immediate-Release Tacrolimus to Once-Daily Prolonged-Release Tacrolimus: A 12-Month Observational Study in Routine Clinical Practice in Germany (ADAGIO)
6. Noninvasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometric Analysis of Urine Samples: A Multicenter Diagnostic Phase III Trial
7. A paired-kidney allocation study found superior survival with HLA-DR compatible kidney transplants in the Eurotransplant Senior Program
8. Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy
9. Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials
10. Rescue allocation and recipient oriented extended allocation in kidney transplantation—influence of the EUROTRANSPLANT allocation system on recipient selection and graft survival for initially nonaccepted organs
11. The Author’s Reply
12. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial
13. Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study
14. Sirolimus in renal transplant recipients with malignancies in Germany
15. Urinary Calprotectin Differentiates Between Prerenal and Intrinsic Acute Renal Allograft Failure
16. Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial
17. Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach
18. Feasibility and Potential of Transcriptomic Analysis Using the NanoString nCounter Technology to Aid the Classification of Rejection in Kidney Transplant Biopsies
19. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial
20. Secreted frizzled-related protein 4 predicts progression of autosomal dominant polycystic kidney disease
21. MO930BURDEN OF DISEASE IN INCIDENT DIALYSIS PATIENTS WAIT LISTED FOR KIDNEY TRANSPLANTATION 2008 – 2016 IN GERMANY
22. Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study
23. Should kidney allografts from old donors be allocated only to old recipients?
24. Everolimus in patients with autosomal dominant polycystic kidney disease
25. Proteinuria and sirolimus after renal transplantation: a retrospective analysis from a large German multicenter database
26. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study
27. Impact of de novo donor-specific HLA antibodies detected by Luminex solid-phase assay after transplantation in a group of 88 consecutive living-donor renal transplantations
28. Determinants of Successful Use of Sirolimus in Renal Transplant Patients
29. Erfolgreiche Rapamycin-Therapie bei idiopathischer pulmonaler Fibrose (IPF) im Präfinalstadium
30. Sirolimus in renal transplantation
31. Zusammenhang zwischen akuter und chronischer Abstoßungsreaktion nach Nierentransplantation
32. Mycophenolate mofetil maintenance therapy in renal transplant patients: long-term results of the TranCept STAY study
33. RENAL FUNCTION OF AN EVEROLIMUS BASED THERAPY AFTER CALCINEURIN INHIBITOR WITHDRAWAL IN MAINTENANCE RENAL TRANSPLANT RECIPIENTS: 2 YEAR FOLLOW-UP DATA OF THE APOLLO TRIAL: RO-185
34. IMPROVED RENAL FUNCTION OF AN EVEROLIMUS/ENTERIC-COATED MYCOPHENOLATE SODIUM REGIMEN AFTER CALCINEURIN INHIBITOR WITHDRAWAL IN DE NOVO RENAL TRANSPLANT PATIENTS: 3 YEAR FOLLOW-UP OF THE ZEUS TRIAL: O-199
35. P1550ACCESS TO KIDNEY TRANSPLANTATION IN A NON-PROFIT FACILITY IN GERMANY
36. Should kidney allografts from old donors be allocated only to old recipients?
37. Repeated kidney re‐transplantation—the Eurotransplant experience: a retrospective multicenter outcome analysis
38. Kidney transplantation in a patient with congenital vena cava and right vena iliaca communis hypoplasia
39. Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR)
40. Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation
41. Chronic allograft nephropathy – a clinical syndrome: early detection and the potential role of proliferation signal inhibitors
42. EC-MPS IS ASSOCIATED WITH SUPERIOR EFFICACY OUTCOMES COMPARED TO MMF IN DE NOVO KIDNEY TRANSPLANT PATIENTS: A POOLED ANALYSIS: O-302
43. SOTRASTAURIN AND MYCOPHENOLIC ACID IN DE NOVO RENAL TRANSPLANT PATIENTS: EFFICACY AND SAFETY OF A CNI-FREE REGIMEN: O-29
44. Sirolimus in renal transplant recipients with malignancies in Germany.
45. Chronic allograft nephropathy—clinical guidance for early detection and early intervention strategies
46. Bone disease after renal transplantation
47. Use of proliferation signal inhibitors in the management of post-transplant malignancies—clinical guidance
48. ‘Old-for-old’—new strategies for renal transplantation
49. Acute effect of cyclosporin on renal function following the initial changeover to a microemulsion formulation in stable kidney transplant patients
50. POSITIVE IMPACT ON HEALTH RELATED QUALITY OF LIFE (HRQL) IN PATIENTS CONVERTED FROM MYCOPHENOLATE-MOFETIL (MMF) TO ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) DUE TO GASTROINTESTINAL (GI) COMPLAINTS: OR-096.5
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.